Here's the hard, cold reality: Despite what the perception is, many people taking GLP-1 medications like Ozempic will drop pounds, but remain obese and overweight. This may sound like a disappointing outcome, but for some patients who are trying to lose large amounts of weight, the results from the drugs can still be life-changing. It can mean the difference between qualifying for bariatric surgery or not.
mountain Inspire Medical shares over the past year Inspire Medical's shares have be suffering for some time now. The stock lost 19.2% of its value in 2023, and is down another 22% since the start of this year. Much of the pressure has come from fears that new anti-obesity medications will reduce its market opportunity.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: